Catalent Valuation
| CTLTDelisted Stock | USD 63.48 0.01 0.02% |
At this time, the firm appears to be overvalued. Catalent shows a prevailing Real Value of $52.89 per share. The current price of the firm is $63.48. Our model approximates the value of Catalent from analyzing the firm fundamentals such as Current Valuation of 16.13 B, return on equity of -0.11, and Profit Margin of (0.09) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Catalent's price fluctuation is very steady at this time. Calculation of the real value of Catalent is based on 3 months time horizon. Increasing Catalent's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Catalent's intrinsic value may or may not be the same as its current market price of 63.48, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 63.48 | Real 52.89 | Hype 63.47 |
The intrinsic value of Catalent's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Catalent's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Catalent helps investors to forecast how Catalent stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Catalent more accurately as focusing exclusively on Catalent's fundamentals will not take into account other important factors: Catalent Total Value Analysis
Catalent is currently expected to have valuation of 16.13 B with market capitalization of 11.52 B, debt of 4.92 B, and cash on hands of 345 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Catalent fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
16.13 B | 11.52 B | 4.92 B | 345 M |
Catalent Investor Information
About 88.0% of the company shares are held by institutions such as insurance companies. The book value of Catalent was currently reported as 19.52. The company recorded a loss per share of 2.28. Catalent had not issued any dividends in recent years. Based on the key indicators related to Catalent's liquidity, profitability, solvency, and operating efficiency, Catalent is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Catalent Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The newest return on assets of Catalent implies not a very effective usage of assets in January.Catalent Ownership Allocation
Catalent holds a total of 181.51 Million outstanding shares. The majority of Catalent outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Catalent to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Catalent. Please pay attention to any change in the institutional holdings of Catalent as this could imply that something significant has changed or is about to change at the company. On December 6, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Catalent's common stock.Catalent Profitability Analysis
The company reported the previous year's revenue of 4.38 B. Net Loss for the year was (1.04 B) with profit before overhead, payroll, taxes, and interest of 1.04 B.About Catalent Valuation
The delisted stock valuation mechanism determines Catalent's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Catalent based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Catalent. We calculate exposure to Catalent's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Catalent's related companies.Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey. Catalent operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 19000 people.
Catalent Growth Indicators
Investing in growth stocks can be very risky. If the company such as Catalent does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 181 M | |
| Quarterly Earnings Growth Y O Y | -0.154 | |
| Forward Price Earnings | 5000 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Catalent Stock
If you are still planning to invest in Catalent check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalent's history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Stocks Directory Find actively traded stocks across global markets |